Macrolide Compounds with Naphthyridinyl Substitutions for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a growing need for new macrolide compounds that can effectively target resistant bacterial organisms, improve safety, and expand the activity spectrum, as existing macrolides face challenges with emerging resistance and limited efficacy against certain pathogens.
Innovation Solution
Development of specific macrolide compounds of Formula (I), including derivatives with 3-hydroxy-naphthyridin-4-yl substitutions, which are effective against resistant bacteria such as Streptococcus pneumoniae and Haemophilus influenzae, utilizing a synthesis process involving acid catalysts, polar aprotic solvents, and reducing agents to create pharmaceutical compositions for treating bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing macrolides are used to treat bacterial infections, then they provide antibacterial activity against susceptible organisms, but they fail to effectively target resistant bacterial strains
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at defined positions of the macrolide core structure. The 3-hydroxy-naphthyridin-4-yl group is placed at the C-11 position, while R1 groups are positioned at C-6 or C-12, creating localized modifications that enhance binding affinity to bacterial ribosomes while maintaining activity against resistant strains.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of macrolides through different R1 substituents (hydrogen, fluorine, alkyl, alkoxy, halogen, cyano, nitro, amino groups) and different core modifications (ketolide, azalide variants). These structural parameter changes result in compounds with improved potency, altered metabolic stability, and expanded activity against macrolide-resistant organisms.
2Reliability
If macrolide compounds are developed to target resistant organisms, then antibacterial activity improves, but metabolic properties and drug interaction potential may worsen
Solution Approach 1:
The patent applies mechanics substitution by replacing the traditional macrolide lactone ring system with ketolide and azalide variants that have modified metabolic pathways. The 3-hydroxy-naphthyridin-4-yl substitution at C-11 creates a structurally distinct compound that is less susceptible to hepatic metabolism by cytochrome P450 enzymes, thereby reducing drug-drug interactions while maintaining antibacterial efficacy.
3Reliability
If structural modifications are introduced to improve antibacterial activity, then effectiveness against resistant organisms increases, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the macrolide molecule into distinct functional domains: the cladinose sugar at C-3, the desosamine sugar at C-5, the C-6/C-12 substituent (R1), and the C-11 3-hydroxy-naphthyridin-4-yl group. This segmentation allows for independent optimization of each domain's contribution to binding affinity and metabolic stability, simplifying the design process despite the overall molecular complexity.
Data Source
AI summary
The invention relates to compounds of Formula (I) wherein R1, R2, and X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of Formula (I).